

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound comprising Oxamide derivatives of formula
I

A-D-B (I)

wherein

D is a bivalent oxamide moiety, or a derivative ~~thereof~~ thereof,

A is ~~a~~an unsubstituted or substituted moiety of up to 40 carbon atoms of the formula: $-L-(M-L')_{\alpha}$, ~~where~~ wherein L is a 5, 6 or 7 membered cyclic structure, ~~preferably~~ selected from the group consisting of aryl, heteroaryl, arylene and heteroarylene, bound directly to D, L' comprises an optionally substituted cyclic moiety having at least 5 members, ~~preferably~~ selected from the group consisting of aryl, heteroaryl, aralkyl, cycloalkyl and heterocyclyl, M is a bond or a bridging group having at least one atom, α is an integer of from 1-4; and each cyclic structure of L and L' contains 0-4 members ~~of~~ selected from the group consisting of nitrogen, oxygen and sulfur, wherein L' is ~~preferably~~ substituted by at least one substituent selected from the group consisting of $-SO_{\beta}R_x$, $-C(O)R_x$ and $-C(NR_y)R_z$

B is a substituted or unsubstituted, ~~up to~~ tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms, ~~preferably of up to 20 carbon atoms~~, comprising at least one 5-, 6-, or 7-membered cyclic structure, ~~preferably~~ a 5- or 6-membered cyclic structure, bound directly to D containing 0-4 members ~~of~~ selected from the group consisting of nitrogen, oxygen and sulfur, wherein said cyclic structure directly bound to D is ~~preferably~~

selected from the group consisting of aryl, heteroaryl and heterocyclyl, R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from the group consisting of N, S and O and optionally halosubstituted, ~~up to per halo,~~

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by halogen, hydroxy ~~and~~ or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from the group consisting of N, S and O and are optionally substituted by a halogen;

R_x is R_z or NR_aR_b , where R_a and R_b are

a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by halogen, hydroxy ~~and~~ or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from the group consisting of N, S and O and are optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by halogen, hydroxy ~~and~~ or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from the group consisting of N, S and O and are optionally substituted by a halogen;

or

- b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from the group consisting of N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from the group consisting of N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from the group consisting of N, S and O and are optionally substituted by a halogen; or
- c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by a halogen;
- where B is substituted, L is substituted or L' is ~~additionally~~ substituted, the substituents are selected from the group consisting of a halogen, ~~up to per halo~~, and W_γ , where γ is 0-3;
- wherein each W is independently selected from the group consisting of $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, $-Q-Ar$, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by one or more substituents independently selected from the groups consisting of $-CN$, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$ and halogen ~~up to per halo~~; with each R^5 independently selected from H or a carbon based

moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N(R⁵)-, -(CH₂)_β, -C(O)-, -CH(OH)-, -(CH₂)_βO-, -(CH₂)_βS-, -(CH₂)_βN(R⁵)-, -O(CH₂)_β, -CHHal-, -CHal₂-, -S-(CH₂)- ~~and~~ or -N(R⁵)(CH₂)_β- where β = 1-3, and Hal is halogen; and Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, ~~which is~~ optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{δ1} wherein δ1 is 0 to 3 and each Z is independently selected from the group consisting -CN, -CO₂R⁵, -C(O)NR⁵R⁵, -C(O)-R⁵, -NO₂, -OR⁵, -SR⁵, -SO₂R⁵, -SO₃H, -NR⁵R⁵, -NR⁵C(O)OR⁵, -NR⁵C(O)R⁵, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from the group consisting of N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁵, -C(O)NR⁵R⁵, -C(O)-R⁵, -NO₂, -OR⁵, -SR⁵, -SO₂R⁵, -SO₃H, -NR⁵R⁵, -NR⁵C(O)OR⁵, -NR⁵C(O)R⁵, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

2. (Currently amended) ~~The compound Oxamide derivative~~ according to claim 1, ~~characterised in that~~ wherein each M independently from one another ~~represents~~ is a bond or is a bridging group, selected from the group consisting of (CR⁵R⁵)_h, ~~or~~ and (CHR⁵)_h-Q-(CHR⁵)_i, wherein


Q is selected from a group consisting of O, S, N-R⁵, (CHal₂)_j, (O-CHR⁵)_j, (CHR⁵-O)_j, CR⁵=CR⁵, (O-CHR⁵CHR⁵)_j, (CHR⁵CHR⁵-O)_j, C=O, C=S, C=NR⁵, CH(OR⁵), C(OR⁵)(OR⁵), C(=O)O, OC(=O), OC(=O)O, (C=O)N(R⁵)C(=O), OC(=O)N(R⁵), N(R⁵)C(=O)O, CH=N-NR⁵, S=O, SO₂, SO₂NR⁵ ~~and~~ and NR⁵SO₂, wherein

R^5 is in each case independently selected from ~~the meanings given above,~~
preferably the group consisting of hydrogen, halogen, alkyl, aryl, and
aralkyl,

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, ~~preferably 0, 1, 2~~
or 3, and

j is 0, 1, 2, 3, 4, 5 or 6, ~~preferably 0, 1, 2 or 3~~.

3. (Currently amended) ~~The compound Oxamide derivative~~ according to claim 1,
~~selected from the compounds of~~ comprising formula II,



wherein

Ar^1, Ar^2 are selected independently from one another from aromatic
hydrocarbons containing 6 to 14 carbon atoms and ethylenical
unsaturated or aromatic heterocyclic residues containing 3 to 10
carbon atoms and one or two hetero atoms, independently selected
from the group consisting of N, O ~~and~~ and S,

R^8, R^9 and R^{10} are independently selected from a group consisting of H, A,
cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$,
 $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$,
 $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$,
 $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$,
 $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$,
 $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$,

$(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$,
 $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,
 $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$,
 $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$,
 $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{11}$,
 $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$,
 $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$,
 $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$,
 $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, wherein

R^{11} , R^{12} are independently selected from a group consisting of H, A,
 $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,

R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or
7-membered ~~heterocycle~~ heterocycles which optionally contains 1
or 2 additional hetero atoms, selected from the group consisting of
N, O and S,

R^{13} , R^{14} are independently selected from a group consisting of H, Hal, A,
 $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl,
alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3 , Ar^4 are independently ~~from one another~~ aromatic hydrocarbon residues
comprising 5 to 12 ~~and preferably 5 to 10~~ carbon atoms ~~which are~~
optionally substituted by one or more substituents, selected from a
the group consisting of A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$,
 $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} ,
 $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,

R¹⁵, R¹⁶ are independently selected from a group consisting of H, A, and (CH₂)_mAr⁵, wherein

Ar⁵ is a 5- or 6-membered aromatic hydrocarbon ~~which is~~ optionally substituted by one or more substituents selected from a the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,

k, m
and n are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is (CR¹¹R¹²)_h, or (CHR¹¹)_h-Q-(CHR¹²)_i, wherein

Q is selected from a the group consisting of O, S, N-R¹⁵, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁵)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=)N(R¹⁵), N(R¹⁵)C(=O), CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵ ~~and~~ and NR¹⁵SO₂, wherein

R¹⁸, R¹⁹, R²⁰ are independently selected from ~~the meanings given for~~ R⁸, R⁹ and R¹⁰,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

j is 1, 2, 3, 4, 5 or 6,

Y is selected from the group consisting of O, S, NR^{21} , $\text{C(R}^{22}\text{)-NO}_2$, $\text{C(R}^{22}\text{)-CN}$ and C(CN)_2 , wherein

R^{21} is independently selected from ~~the meanings given for~~ R^{13} , R^{14} , and

R^{22} is independently selected from ~~the meanings given for~~ R^{11} , R^{12} ,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, ~~preferably 0, 1 or 2,~~


u is 0, 1, 2 or 3, ~~preferably 0, 1 or 2,~~


and

Hal is independently selected from a the group consisting of F, Cl, Br and I;


and the pharmaceutically acceptable derivatives, salts and solvates thereof.

4. (Currently amended) The compound ~~Oxamide derivative~~ according to claim 3, selected from the compounds of formula IIa, IIb, IIc, IId, IIe, IIg and IIh,







IIb




IIc




IIId




IIe



IIIf



IIg



wherein R^6 , R^7 , R^8 , p , X , Y , R^9 , q are as defined in claim 3 and R^{10} is H or as defined in claim 3;

and the pharmaceutically acceptable derivatives, salts and solvates thereof.

5. (Currently amended) The compound ~~Oxamide derivative~~ according to claim 1, selected from the compounds (1) to (224) of table 1, and the pharmaceutically acceptable derivatives, salts and solvates thereof.

6. (Currently amended) The compound ~~Oxamide derivative~~ according to claim 1 as wherein said compound is a medicament.

7. (Currently amended) The compound ~~Oxamide derivative~~ according to claim 1 as wherein said compound is a kinase inhibitor.

8. (Currently amended) The compound ~~Oxamide derivative~~ according to claim 7, ~~characterized in that~~ wherein the kinase inhibitor inhibits a raf-kinase ~~kinases are selected from raf-kinases~~.

9. (Currently Amended) A Pharmaceutical composition, ~~characterized in that it contains~~ comprising one or more of the compounds according to claim 1.

10. (Currently Amended) The Pharmaceutical composition according to claim 9, ~~characterised in that it contains~~ comprising one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients other than the compounds according to claim 9.

11. (Currently Amended) ~~A P~~process for the manufacture of a pharmaceutical composition, ~~characterised in that comprising mixing~~ one or more compounds according to claim 1 ~~and with~~ one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to claim 1, ~~is processed~~ by mechanical means into a pharmaceutical composition that is suitable as dosage form for application ~~and/or~~ or administration to a patient.

12. (Currently amended) ~~Use of a~~ The compound according to claim 1 as wherein said compound is a pharmaceutical.

13. (Currently Amended) ~~Use of a compound according to claim 1 in the treatment and/or prophylaxis of disorders~~ A method of treatment or prophylaxis of disorders comprising administering a patient in need thereof, an effective amount of the compound according to claim 1.

14. (Currently Amended) ~~Use of a compound according to claim 1 for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders~~ A method of treatment or prophylaxis of disorders comprising administering a patient in need thereof, a pharmaceutical composition comprising an effective amount of the compound according to claim 1.

15. (Currently Amended) ~~Use~~ The method according to claim 13, ~~characterised in that wherein~~ the disorders are caused, mediated ~~and/or~~ or propagated by raf-kinases.

16. (Currently Amended) ~~Use~~ The method according to claim 13, ~~characterised in that wherein~~ the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

17. (Currently Amended) ~~Use~~ The method according to claim 13, ~~characterised in that wherein~~ the disorder is cancer.

18. (Currently Amended) Use The method according to claim 13, ~~characterised in that~~ wherein the disorder is noncancerous.

19. (Currently Amended) Use The method according to claim 13, ~~characterised in that~~ wherein the noncancerous disorders are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

20. (Currently Amended) Use The method according to claim 13, ~~characterised in that~~ wherein the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

21. (Currently Amended) Use The method according to claim 15, ~~characterised in that~~ wherein the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative diseases.

22. (Currently Amended) Use The method according to claim 15, ~~characterised in that~~ wherein the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.

23. (Currently amended) ~~Use of a~~ The compound according to claim 1 as wherein said compound is a raf-kinase inhibitor.

24. (Currently amended) Use The compound according to claim 23, ~~characterised in that~~ wherein the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf-1.

25. (Currently Amended) A Mmethod for the treatment ~~and/or~~ or prophylaxis of disorders, ~~characterised in that~~ wherein one or more compounds according to claim 1 is administered to a patient in need of such a treatment.


26. (Currently Amended) The Mmethod according to claim 25, wherein the one or more compounds are administered as a pharmaceutical composition. ~~characterised in that the one or more compounds according to one of the claims claim 1 to 5 are administered as a pharmaceutical composition according to claim 9 or 10.~~

27. (Currently Amended) The Mmethod for the treatment ~~and/or~~ or prophylaxis of disorders according to claim 26, ~~characterized in that~~ wherein the disorder is caused, medicated ~~and/or~~ or propagated by raf-kinase.

28. (Currently amended) The Mmethod ~~for the treatment~~ according to claim 27, ~~characterised in that~~ wherein the disorder is cancerous cell growth mediated by raf-kinase.

29. (Currently amended) A Mmethod for producing compounds of formula II, ~~characterised in that~~ comprising, reacting

a) a compound of formula III




wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^8 ,
 p , Ar^1 , Y are as defined in claim 3,

~~is reacted~~

b) with a compound of formula IV,




wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^9 , q , X , Ar^2 ,
 R^{10} and r are as defined in claim 3,

and optionally

c) isolating ~~and/or~~ or treating the compound of formula II obtained by said
reaction with an acid, to obtain the salt thereof.


30. (Currently amended) A compound of formula III,



wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^8 ,
 p , Ar^1 , Y are as defined in claim 3.

31. (Currently amended) A compound of formula IV,




wherein

L^2, L^3 are independently from one another H or a metal ion, and R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3.

32. (New) The compound according to claim 1, wherein said compound is an oxamide derivative.

33. (New) The compound comprising formula II,



wherein

Ar^1, Ar^2 are selected independently selected from one another from a group consisting of aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from the group consisting of N, O and S, or ONC_3H_2 ,

R^8, R^9 and R^{10} are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$,

$C(R^{13})HCOOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$,
 $CH=CHCOOR^{11}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$,
 $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$,
 $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$,
 $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$,
 $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, wherein

R^{11} , R^{12} are independently selected from a group consisting of H, A,
 $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they
are bound to, a 5-, 6- or 7-membered heterocycles which optionally contains 1 or 2 additional
hetero atoms, selected from the group consisting of N, O and S,

R^{13} , R^{14} are independently selected from a group consisting of H, Hal, A,
 $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl,
alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3 , Ar^4 are independently aromatic hydrocarbon residues comprising 5 to
12 carbon atoms optionally substituted by one or more substituents, selected from the group
consisting of A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, NR^{15}
 $CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is
optionally substituted by one or more substituents, selected from a group consisting of A, Hal,
 NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$,
 COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15} , R^{16} are independently selected from a group consisting of H, A, and
 $(CH_2)_mAr^5$, wherein

Ar^5 is a 5- or 6-membered aromatic hydrocarbon optionally substituted
by one or more substituents selected from the group consisting of methyl, ethyl, propyl,
2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3 ,

k, m and n are independently of one another 0, 1, 2, 3, 4, or 5;

X is selected from the group consisting of O, S, and CH_2 ,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3, and

Hal is independently selected from the group consisting of F, Cl, Br and I; and the pharmaceutically acceptable derivatives, salts and solvates thereof.